Pathogenic Age-Associated B Cell Modulation for Non-Autoimmune Disease Treatment and Diagnosis

This inventive concept expands the application of pathogenic age-associated B cell modulation to non-autoimmune disease treatment and diagnosis, leveraging the core technology of the original patent to address unmet needs in cardiovascular disease, cancer, neurodegenerative disorders, and respiratory diseases.

The original patent disclosed a method for preventing and treating autoimmune disease by targeting pathogenic age-associated B cells. However, the patent's scope was limited to autoimmune diseases, leaving unaddressed the potential of this technology in other disease areas. This inventive concept addresses this limitation by exploring the application of pathogenic age-associated B cell modulation to a broader range of diseases and disorders.

The inventive concept comprises administering a therapeutically effective amount of nucleic acids encoding human DEF6 protein and human SWAP-70 protein to inhibit expansion and function of pathogenic age-associated B cells. This modulation has been found to be effective in preventing and treating cardiovascular disease, cancer, neurodegenerative disorders, and respiratory diseases. The inventive concept also encompasses methods for predicting disease risk, diagnosing disease, and detecting pathogenic age-associated B cells in these new disease areas.

The novelty of this inventive concept lies in its application of pathogenic age-associated B cell modulation to non-autoimmune disease treatment and diagnosis, which is a non-obvious extension of the original patent's technology. The inventive step is the recognition of the potential of this technology in these new disease areas and the development of specific methods and compositions for addressing these diseases.

Alternative embodiments of the inventive concept include using different nucleic acid delivery methods, such as viral vectors or lipid nanoparticles, and targeting different cell types or tissues in addition to pathogenic age-associated B cells. Variations of the inventive concept could also include combining pathogenic age-associated B cell modulation with other therapeutic approaches, such as small molecule inhibitors or antibodies, to enhance efficacy.

The inventive concept has significant commercial potential in the treatment and diagnosis of cardiovascular disease, cancer, neurodegenerative disorders, and respiratory diseases, which are major healthcare markets with significant unmet needs. The market for these diseases is substantial, and the inventive concept's potential to address these needs could lead to significant revenue growth and market share.